New Discovery Could Rewrite Alzheimer's Research
Scientists believed the P3 peptide was harmless, but new findings suggest it can form amyloid clumps and may damage neurons.
New research from the University of California Santa Cruz challenges the decades-old understanding of the P3 peptide in Alzheimer's research. According to Professor Jevgenij Raskatov, the P3 peptide, previously considered harmless, may form the same amyloid clumps as the suspected primary culprit, beta-amyloid.
In a commentary published in the journal ChemBioChem, Raskatov proposes that the P3 peptide can influence how beta-amyloid aggregates and its toxicity. These findings suggest that P3 could also contribute to neuron damage associated with Alzheimer's disease. Raskatov suggests renaming the peptide to alpha-amyloid (Aα).
Treatment development for Alzheimer's disease has long focused on beta-amyloid, particularly its Aβ40 and Aβ42 fragments. Aβ42 has been most scrutinized for its tendency to form toxic aggregates.
The P3 peptide is generated when the APP (amyloid precursor protein) is processed by different enzymes. It was previously assumed that P3 remained soluble and did not form harmful clumps. However, Raskatov questions whether these assumptions were ever adequately tested.
Further research is needed to clarify the precise role of the P3 peptide in Alzheimer's disease. Nevertheless, the discoveries may open new avenues for understanding the disease's pathogenesis and potential therapeutic targets.